A new generation of inhaled insulin is inching closer to market, as a little-known biopharmaceutical company is gearing up for late-stage clinical research and FDA filing, and has just hired a seasoned CEO to lead commercialization efforts. You may remember Dance Biopharm, the San-Francisco area startup that came on the scene in roughly 2010, after Pfizer’s failed “bong-style” Exubera inhaled insulin was pulled from market and when MannKind’s Afrezza was still in development. This startup has been working to create a whole new type of inhaled insulin for almost a decade.
Read more here: Are We Ready For Inhalable Insulin 3.0? | DiabetesMine
